This document lists the medicines eligible for supply through the Northern Ireland MHRA Authorised Route (NIMAR).
From 1 January 2022, the listed medicines may be dispatched from Great Britain to Northern Ireland on the basis of the medicines authorisation in Great Britain.
This list is maintained and published in accordance with regulation 167B (list of NIMAR products) of the Human Medicines Regulations 2012 (SI 2012/1916, as amended).
Published 16 December 2021 Last updated 7 July 2023 +show all updates
Added to the list:(Toujeo 300units/ml solution for injection 3ml pre-filled DoubleStar pens) Insulin glargine 300units/ml solution for injection 3ml pre-filled disposable devices;(Fiasp FlexTouch 100units/ml solution for injection 3ml pre-filled pens) Insulin aspart 100units/ml solution for injection 3ml pre-filled disposable devices;(Avamys 27.5micrograms/dose nasal spray) Fluticasone furoate 27.5micrograms/dose nasal spray;Tedizolid 200mg tablets.Removed from the list:(Palexia SR 100mg tablets) Tapentadol 100mg modified-release tablets;(Palexia SR 150mg tablets) Tapentadol 150mg modified-release tablets;(Palexia SR 200mg tablets) Tapentadol 200mg modified-release tablets;(Palexia SR 50mg tablets) Tapentadol 50mg modified-release tablets;(Palexia 50mg tablets) Tapentadol 50mg tablets;(Palexia 75mg tablets) Tapentadol 75mg tablets.
The following products have been added to the list: Gemcitabine 1.2g/120ml infusion bags; Gemcitabine 1.4g/140ml infusion bags; Gemcitabine 1.6g/160ml infusion bags; Gemcitabine 1.8g/180ml infusion bags; Gemcitabine 2.2g/220ml infusion bags; Gemcitabine 2g/200ml infusion bags; and Semaglutide 1mg/0.74ml solution for injection 3ml pre-filled disposable device.